Mobocertinib: EGFR Exon 20 Inhibitor for Lung Cancer
Mobocertinib is an oral, irreversible tyrosine kinase inhibitor specifically designed to selectively target mutant forms of the epidermal growth factor receptor (EGFR) with exon 20 insertion mutations (EGFRex20ins). This mutation accounts for approximately 10–12% of all EGFR mutations in non-small cell lung cancer and has traditionally been poorly responsive to standard EGFR inhibitors (erlotinib, gefitinib, osimertinib).
Mobocertinib covalently binds to mutant EGFR, suppressing signaling pathways responsible for tumor cell growth and survival. On Unifarm, you can find generic versions of medications (such as Exkivity) containing this active ingredient.
Indications
- Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations: Treatment of adult patients with locally advanced or metastatic NSCLC whose tumor harbors EGFR exon 20 insertion mutations, as detected by a validated test, and who have received at least one prior line of systemic therapy (including platinum-based chemotherapy).
Note: In 2023, the manufacturer voluntarily withdrew the U.S. indication following confirmatory study results. However, the drug continues to be used in several countries and remains a subject of clinical investigation.
Dosage and administration
Available as capsules for oral administration.
Standard Regimen:
- Recommended Dose: 160 mg orally once daily.
- Administration: Swallow capsules whole with water. Take on an empty stomach (1 hour before or 2 hours after a meal).
- Dose Reduction: For adverse reactions, the dose may be reduced to 120 mg, then to 80 mg once daily.
Treatment should continue until disease progression or unacceptable toxicity. ECG monitoring (QTc interval), electrolytes (potassium, magnesium), cardiac function, and hepatic function should be assessed before and during treatment. Concomitant use with strong or moderate CYP3A4 inhibitors and QT-prolonging drugs should be avoided. Proton pump inhibitors (PPIs) do not affect mobocertinib absorption.
- Hypersensitivity to mobocertinib or any component of the product.
- Pregnancy and breastfeeding (can cause fetal harm).
- Congenital long QT syndrome or clinically significant baseline QTc prolongation.
- Concomitant use with drugs known to significantly prolong the QT interval.
- Severe hepatic impairment (use not studied).
- Uncorrected electrolyte imbalances (hypokalemia, hypomagnesemia).
Mobocertinib therapy requires careful cardiac monitoring and electrolyte assessment. Common adverse reactions include:
- Gastrointestinal: Diarrhea (very common, can be severe — key adverse effect), nausea, vomiting, decreased appetite, stomatitis.
- Cardiovascular: QTc prolongation (serious, dose-dependent risk; regular ECG monitoring required), cardiac failure (rare).
- Dermatologic: Rash, paronychia, dry skin, acneiform eruptions.
- Hepatic: Elevated transaminases (ALT, AST), increased bilirubin.
- General: Fatigue, weight loss, muscle spasms.
- Hematologic: Anemia, lymphopenia, thrombocytopenia.
- Renal: Increased creatinine.
- Pulmonary: Interstitial lung disease (ILD) / pneumonitis (rare but serious).
